Navigation Links
Noninvasive Breath Test Predicts Survival in Patients with Viral Hepatitis
Date:11/2/2009

ALEXANDRIA, Va. and BOSTON, Nov. 2 /PRNewswire/ -- A methacetin breath test (MBT) that can be performed quickly and noninvasively has been proven to accurately predict survival in patients with viral hepatitis and may be used as an adjunctive tool to MELD. "The breath test has to be validated on a large cohort of patients," said Gadi Lalazar, MD, principal investigator on this study "but if it is validated, this non invasive liver function test will be able to identify liver impairment at all stages of liver disease - both acute and chronic."

MELD (Model for End-Stage Liver Disease) is a scoring system adopted by the United Network for Organ Sharing to assess liver disease severity and determining 3-month mortality. Viral hepatitis progresses at an unpredictable rate and the addition of another way of assessing disease progression can serve as an important adjunct to MELD.

Researchers studied 395 patients with viral hepatitis. The MBT accurately predicted survival. Of those patients, 11 had died in the two years in which data were collected. MBT identified 9 of these 11 patients as being high risk. Whereas 6 of those 11 deaths occurred in patients with a MELD score less than 15 - patients who were considered at a low risk by the MELD scoring system. In addition, MBT accurately predicted survival in patients with a higher MELD score and, therefore, at increased risk as defined by MELD.

They concluded that MBT may increase physicians' ability to identify at-risk patients and allow those patients to be listed for liver transplantation earlier than using MELD alone to determine mortality. "We are now conducting large scale clinical trials to assess the role of the methacetin breath test for follow up and therapeutic decision making in patients with chronic hepatitis B and in non-alcoholic fatty liver disease," said Dr. Lalazar.

Abstract title:

The noninvasive 13C methacetin breath test accurately predicts long-term survival in patients with chronic viral hepatitis and may serve as an adjunctive tool to MELD: Results of a 395-patient clinical trial

About the AASLD

AASLD is the leading medical society focused solely on advancing the science and practice of hepatology and represents more than 3,300 practitioners, researchers, and allied health professionals worldwide. Founded by physicians in 1950, AASLD has upheld the standards of the profession and fostered research that generates treatment options for the millions of patients with liver diseases.

This year's Liver Meeting, held in Boston, Massachusetts, October 30 - November 3, will bring together more than 7,000 researchers from 55 countries. A pressroom will be available from October 31 at the annual meeting. For copies of abstracts and press releases, or to arrange for pre-conference research interviews contact Gregory Bologna at 703-299-9766. To pre-register, call Ann Tracy at 703-299-9766.

Press releases, additional information for the media, and all abstracts are available online at www.aasld.org.

    Media Contact: Gregory Bologna
    703/299-9766
    gbologna@aasld.org
    Press Room: October 31 - November 3, 2009
    Hynes Convention Center, Room 209
    Telephone: (617) 954-2827

    Researcher: Gadi Lalazar, MD
    Email: lalazar@hadassah.org.il
    Phone: 97 202 67777 816

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com

SOURCE American Association for the Study of Liver Diseases


'/>"/>
SOURCE American Association for the Study of Liver Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns
2. New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
3. Saint Josephs Hospital First in Georgia to Offer Noninvasive Treatment of Brain Disorders with Leksell Gamma Knife Perfexion
4. Noninvasive Medical Technologies Awarded ISO 13485 Quality Certification
5. New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology
6. Harris Methodist Fort Worth Hospital Using Bubbles to Help Babies Breathe
7. Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital
8. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
9. DNA Test Predicts Harmful Effects of Cancer Drug
10. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
11. Simple Test Accurately Predicts Risk of Serious Jaundice in Newborns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):